Company description

REGENXBIO Inc. (RGNX) is a leading clinical-stage biotechnology company focused on developing life-changing gene therapies to treat rare genetic diseases. Founded in 2008, the company utilizes its proprietary NAV® Technology Platform to deliver durable and potentially curative treatments for a wide range of genetic disorders. Their expertise lies in developing gene therapies that target one-time treatments, such as AAV-mediated gene therapies, to treat diseases with significant unmet needs. RGNX has a robust pipeline of product candidates in various stages of development, with their lead candidate, RGX-314, currently in Phase II and Phase III clinical trials for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy. They have also formed strategic partnerships with major pharmaceutical companies such as Pfizer and AstraZeneca to advance their pipeline and bring their innovative therapies to patients in need. As a testament to their success, RGNX has received numerous industry awards and recognition, including being named one of the top 20 most innovative biotech companies by Forbes magazine. With a strong focus on research and development and a commitment to making a positive impact on patients' lives, RGNX is positioned for continued growth and success in the ever-evolving biotechnology industry.